Expert Interview
Discussing the FDA approval of Wegovy® in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease.
Ticker(s): NVOInstitution: HCA HEALTHCARE
- Cardiologist in practice for over 11 years.
- Currently manages 30 patients that have both nHCM and Chronic Stable Angina.
- Has reviewed both Phase 2 trials IMPROVE-HCM and IMPROVE-ISCHEMIA, evaluating Ninerafaxstat and can discuss.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
